HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

513.048

-0.450-0.09%

Number of Gainers:28

Number of Losers:19

Number of Flat:8

PE:- -

High:516.134

Open:513.498

Low:507.279

Close:513.498

Loading ...

Hansoh Pharmaceutical - Units Entered Into a License Agreement With Regeneron Pharmaceuticals

THOMSON REUTERS

Hansoh Pharmaceutical - Licensors Shall Grant an Exclusive Worldwide License to Develop, Manufacture and Commercialize Hs-20094

THOMSON REUTERS

Regeneron Secures Global Rights to Novel GLP-1/GIP Receptor Agonist, Expanding Obesity Treatment Portfolio with Strategic In-Licensing from Hansoh Pharmaceuticals

Central China New Life Ltd. Conducted Annual General Meeting

Innovent Biologics Presents Promising Phase 1 Results for IBI363 in Advanced Colorectal Cancer at 2025 ASCO Meeting

2025 Asco Oral Presentation: Innovent Biologics Announces Updated Date of Ibi363 (First-in-Class Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) From Phase 1 Clinical Studies in Advanced Colorectal Cancer

THOMSON REUTERS

Innovent Biologics Announces Groundbreaking Phase 2 Trial of IBI363 for Treatment-Resistant Melanoma at ASCO 2025

Asco 2025 Oral Presentation: Innovent Biologics Announces Updated Data of Ibi363 (First-in-Class Pd-1/Il-2Α -Bias Bispecific Antibody Fusion Protein) From Phase 1 and 2 Clinical Studies on Immunotherapy-Treated Advanced Malignant Melanoma

THOMSON REUTERS

BRIEF-Hansoh Pharmaceutical Says Third Biologics License Application Of Xinyue (Inebilizumab Injection) Accepted By NMPA

MicroPort CardioFlow Announces Acquisition of Remaining 49% Stake in MP CardioAdvent

Microport Cardioflow Medtech - Total Consideration of Acquisition Is RMB170.9 Mln

THOMSON REUTERS

Microport Cardioflow Medtech - Upon Completion, MP Cardioadvent Will Become a Wholly-Owned Subsidiary of Co

THOMSON REUTERS

Microport Cardioflow Medtech - Microport Sinica and Shanghai Zuoqing Conditionally Agreed to Sell 35.27% and 13.73% Stake in MP Cardioadvent

THOMSON REUTERS

Bairong Inc. Conducted Annual General Meeting

Hygeia Healthcare Unit to Sell Medicine Products to Affiliate

MT Newswires Live

Chinese Regulator Accepts Hansoh Pharmaceutical's License Application for Generalized Myasthenia Gravis Drug

MT Newswires Live

Venus MedTech Hangzhou Inc. Announces Re-election and Appointment of New Directors and Supervisors for the Third Session

Zylox-Tonbridge Medical Technology Co. Ltd. Convened Annual General Meeting

Zylox-Tonbridge Medical Technology Co. Ltd. Announces Final Dividend of RMB 0.1 Per Share for Year Ended 31 December 2024

Hansoh Pharmaceutical - Third Biologics License Application of Xinyue (Inebilizumab Injection) Was Accepted by Nmpa

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1583/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":513.04846,"timestamp":1749197315346,"preClose":513.49805,"halted":0,"volume":787771556,"delay":0,"changeRate":-0.000876,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-0.449585,"latestTime":"06-06 16:00:00","open":513.49805,"high":516.1344,"low":507.27917,"amount":15627538503,"amplitude":0.017245,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749432600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":2.358598,"peRate":21.998152,"turnoverRate":0.005389,"increases":30,"decrements":20,"flats":4,"marketCap":2901322639680,"floatMarketCap":2286727975232},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":516.1344,"amplitude":0.017245,"preClose":513.49805,"low":507.27917,"pbRate":"2.358598","latestPrice":513.04846,"volume":787771556,"delay":0,"open":513.49805,"prevYearClose":446.93042,"prevWeekClose":496.286,"prevMonthClose":496.286,"prevQuarterClose":505.776,"fiveDayClose":496.286,"twentyDayClose":480.539,"sixtyDayClose":530.16,"secType":"PLATE","market":"HK","turnoverRate":0.005389,"peRate":21.998152,"marketCap":2901322639680,"floatMarketCap":2286727975232,"timestamp":1749197315346,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":28,"down":19,"flat":8},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540678037","title":"Hansoh Pharmaceutical - Units Entered Into a License Agreement With Regeneron Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2540678037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540678037?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:07","pubTimestamp":1748862428,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nFWN3S3022:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1589","BK1191","03692","BK1583"],"gpt_icon":0},{"id":"2540476782","title":"Hansoh Pharmaceutical - Licensors Shall Grant an Exclusive Worldwide License to Develop, Manufacture and Commercialize Hs-20094","url":"https://stock-news.laohu8.com/highlight/detail?id=2540476782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540476782?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:07","pubTimestamp":1748862428,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nFWN3S3022:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1583","BK1589","03692"],"gpt_icon":0},{"id":"2540676789","title":"Regeneron Secures Global Rights to Novel GLP-1/GIP Receptor Agonist, Expanding Obesity Treatment Portfolio with Strategic In-Licensing from Hansoh Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2540676789","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540676789?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:06","pubTimestamp":1748862360,"startTime":"0","endTime":"0","summary":"Regeneron Secures Global Rights to Novel GLP-1/GIP Receptor Agonist, Expanding Obesity Treatment Portfolio with Strategic In-Licensing from Hansoh Pharmaceuticals. Regeneron Pharmaceuticals, Inc. has announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited to acquire exclusive clinical development and commercial rights for a dual GLP-1/GIP receptor agonist, HS-20094, outside of the Chinese Mainland, Hong Kong, and Macau. Currently in Phase 3 testing, this therapeutic candidate has been studied in over 1,000 patients as a weekly subcutaneous injection, showing promising efficacy and safety data. The agreement includes an upfront payment of $80 million to Hansoh, with potential additional payments up to $1.93 billion based on achievement of development, regulatory, and sales milestones. Regeneron aims to integrate this candidate into its portfolio to address muscle loss and other obesity-related comorbidities.Disclaimer: This news brief was created b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL7VzY3C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0058720904.USD","IE00BKPKM429.USD","LU2362541513.USD","LU1974910355.USD","BK1583","LU0882574055.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","BK1589","LU2468319806.SGD","LU0320765992.SGD","BK4112","BK4585","LU0053666078.USD","LU2095319765.USD","LU2237438978.USD","LU0823416689.USD","LU0889565916.HKD","LU2362540622.SGD","NDAQ","LU0114720955.EUR","BK1191","LU1917777945.USD","LU2362541273.HKD","REGN","LU0289739699.SGD","IE00BGHQF748.EUR","LU0823434583.USD","LU0109394709.USD","LU2023250504.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","LU0823434740.USD","03692","LU2106854487.HKD","LU2089984988.USD","BK4588"],"gpt_icon":0},{"id":"2540764071","title":"Central China New Life Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540764071","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540764071?lang=en_us&edition=fundamental","pubTime":"2025-06-02 18:30","pubTimestamp":1748860245,"startTime":"0","endTime":"0","summary":"Central China New Life Ltd. held its annual general meeting on 2 June 2025. During the meeting, several proposals were approved. A final dividend of HK$7.36 cents per share for the year ended 31 December 2024 was declared. Mr. Wang Jun was re-elected as an executive Director, Ms. Xin Zhu was re-elected as an independent non-executive Director, and Mr. Guo Liyuan was re-elected as an executive Director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Central China New Life Ltd. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL2SlTh4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1258","BK1542","BK1583","BK1229","09983"],"gpt_icon":0},{"id":"2540753909","title":"Innovent Biologics Presents Promising Phase 1 Results for IBI363 in Advanced Colorectal Cancer at 2025 ASCO Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540753909","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540753909?lang=en_us&edition=fundamental","pubTime":"2025-06-02 08:00","pubTimestamp":1748822424,"startTime":"0","endTime":"0","summary":"Innovent Biologics, Inc. has announced promising results from its Phase 1 studies evaluating IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, in patients with advanced colorectal cancer. The data, presented at the 2025 American Society of Clinical Oncology  Annual Meeting, indicate that IBI363, both as monotherapy and in combination with bevacizumab, shows encouraging responses and overall survival benefits. These findings are particularly noteworthy given colorectal cancer's reputation as an immunologically 'cold' tumor. The studies, conducted in China, the United States, and Australia, underscore IBI363's potential to convert 'cold tumors' into 'hot tumors,' suggesting significant promise for broader clinical development and potential new treatment avenues in immunotherapy-resistant and cold tumor indications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL1f2vDz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK1583","BK1161","BK1147","01801","LU2328871848.SGD","BK1589","01911","LU2488822045.USD"],"gpt_icon":0},{"id":"2540753935","title":"2025 Asco Oral Presentation: Innovent Biologics Announces Updated Date of Ibi363 (First-in-Class Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) From Phase 1 Clinical Studies in Advanced Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2540753935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540753935?lang=en_us&edition=fundamental","pubTime":"2025-06-02 08:00","pubTimestamp":1748822402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA1KZZ4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2488822045.USD","LU1969619763.USD","BK1161","BK1589","LU2328871848.SGD","BK1583","01801"],"gpt_icon":0},{"id":"2540780236","title":"Innovent Biologics Announces Groundbreaking Phase 2 Trial of IBI363 for Treatment-Resistant Melanoma at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540780236","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540780236?lang=en_us&edition=fundamental","pubTime":"2025-06-01 09:39","pubTimestamp":1748741995,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced updated data from its Phase 1 and Phase 2 clinical studies on IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, at the 2025 American Society of Clinical Oncology  Annual Meeting. This study focuses on patients with advanced malignant melanoma, particularly the acral and mucosal subtypes, which are typically resistant to treatment. The research has shown promising results in these hard-to-treat \"cold\" tumors. Innovent Biologics is also conducting a pivotal Phase 2 registrational trial comparing IBI363 monotherapy to pembrolizumab in patients with unresectable, locally advanced, or metastatic mucosal and acral melanoma. The trial aims to enroll 180 patients and will evaluate progression-free survival as the primary endpoint. IBI363 was generally well tolerated, with manageable safety profiles, and no new safety risks were identified.Disclaimer: This news brief was created by Public Technologies  using generative artificial ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nNDL8gJRqs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","01911","01801","BK1583","LU2328871848.SGD","BK1161","LU1969619763.USD","LU2488822045.USD","BK1147"],"gpt_icon":0},{"id":"2540474780","title":"Asco 2025 Oral Presentation: Innovent Biologics Announces Updated Data of Ibi363 (First-in-Class Pd-1/Il-2Α -Bias Bispecific Antibody Fusion Protein) From Phase 1 and 2 Clinical Studies on Immunotherapy-Treated Advanced Malignant Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2540474780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540474780?lang=en_us&edition=fundamental","pubTime":"2025-06-01 09:39","pubTimestamp":1748741981,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nTUA3V3C3R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2488822045.USD","LU2328871848.SGD","BK1589","BK1583","01801","LU1969619763.USD","BK1161"],"gpt_icon":0},{"id":"2539748222","title":"BRIEF-Hansoh Pharmaceutical Says Third Biologics License Application Of Xinyue (Inebilizumab Injection) Accepted By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2539748222","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539748222?lang=en_us&edition=fundamental","pubTime":"2025-05-31 01:31","pubTimestamp":1748626268,"startTime":"0","endTime":"0","summary":"BRIEF-Hansoh Pharmaceutical Says Third Biologics License Application Of Xinyue  Accepted By NMPAMay 30  - Hansoh Pharmaceutical Group Company Ltd 3692.HK:THIRD BIOLOGICS LICENSE APPLICATION OF XINYUE  WAS ACCEPTED BY NMPAFurther company coverage: 3692.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S203N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03692","BK1589","BK1583"],"gpt_icon":0},{"id":"2539275550","title":"MicroPort CardioFlow Announces Acquisition of Remaining 49% Stake in MP CardioAdvent","url":"https://stock-news.laohu8.com/highlight/detail?id=2539275550","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539275550?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:45","pubTimestamp":1748616322,"startTime":"0","endTime":"0","summary":"MicroPort CardioFlow Medtech Corporation announced a discloseable and connected transaction to acquire the remaining 49% equity interest in MP CardioAdvent. This acquisition, detailed in an agreement dated May 30, 2025, involves purchasing approximately 35.27% from MicroPort Sinica and 13.73% from Shanghai Zuoqing. Upon completion, MP CardioFlow will fully own MP CardioAdvent, enhancing its focus on innovative solutions for structural heart diseases. The transaction, subject to regulatory approvals, is significant under the listing rules due to its size.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microport Cardioflow Medtech Corporation published the original content used to generate this news brief on May 30, 2025, and is solely r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL7J0n5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","00853","02160","BK1589","BK1100","BK1574","BK1585"],"gpt_icon":0},{"id":"2539427302","title":"Microport Cardioflow Medtech - Total Consideration of Acquisition Is RMB170.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2539427302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539427302?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:36","pubTimestamp":1748615784,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S230K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1100","BK1574","02160","BK1583"],"gpt_icon":0},{"id":"2539273022","title":"Microport Cardioflow Medtech - Upon Completion, MP Cardioadvent Will Become a Wholly-Owned Subsidiary of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2539273022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539273022?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:36","pubTimestamp":1748615784,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S230K:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1100","BK1583","02160"],"gpt_icon":0},{"id":"2539021273","title":"Microport Cardioflow Medtech - Microport Sinica and Shanghai Zuoqing Conditionally Agreed to Sell 35.27% and 13.73% Stake in MP Cardioadvent","url":"https://stock-news.laohu8.com/highlight/detail?id=2539021273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539021273?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:36","pubTimestamp":1748615784,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S230K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1100","02160","BK1583"],"gpt_icon":0},{"id":"2539427856","title":"Bairong Inc. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539427856","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539427856?lang=en_us&edition=fundamental","pubTime":"2025-05-30 21:51","pubTimestamp":1748613103,"startTime":"0","endTime":"0","summary":"Bairong Inc. held its Annual General Meeting on May 30, 2025. During the meeting, several proposals were put forward and approved. These included the adoption of the audited consolidated financial statements and the reports of the directors and independent auditor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bairong Inc. published the original content used to generate this news brief on May 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDLbBQv9w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1575","BK1583","06608","BK1587","BK1131"],"gpt_icon":0},{"id":"2539227566","title":"Hygeia Healthcare Unit to Sell Medicine Products to Affiliate","url":"https://stock-news.laohu8.com/highlight/detail?id=2539227566","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539227566?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:51","pubTimestamp":1748609465,"startTime":"0","endTime":"0","summary":"Hygeia Healthcare  unit Shanghai Gamma Star Technology Development entered into a framework agreement to supply medicine and medical consumables to Handan Renhe Hospital from time to time as required, a Thursday Hong Kong bourse filing said.The new agreement, which replaces existing procurement contracts, is valid till Dec. 31, 2027.Shanghai Xiangshang Investment Development holds 30% organizer's interest in Handan Renhe Hospital. Shanghai Xiangshang Investment Development is wholly owned by Zhu Yiwen, founder and chairman of Hygeia Healthcare, and his daughter Zhu Jianqiao, also a controlling shareholder of the company.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06078","BK4137","LU0329678337.USD","LU2488822045.USD","LU0737861772.HKD","BK1583","HCSG","LU0329678170.USD","BK1209"],"gpt_icon":0},{"id":"2539222348","title":"Chinese Regulator Accepts Hansoh Pharmaceutical's License Application for Generalized Myasthenia Gravis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2539222348","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539222348?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:23","pubTimestamp":1748607795,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical's  third biologics license application for the Inebilizumab injection was accepted by China's National Medical Products Administration, a Friday filing with the Hong Kong bourse said.The application was with regard to the treatment of generalized myasthenia gravis  in adult patients.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","03692","BK1589","BK1191"],"gpt_icon":0},{"id":"2539221097","title":"Venus MedTech Hangzhou Inc. Announces Re-election and Appointment of New Directors and Supervisors for the Third Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2539221097","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539221097?lang=en_us&edition=fundamental","pubTime":"2025-05-30 19:51","pubTimestamp":1748605879,"startTime":"0","endTime":"0","summary":"Venus MedTech HangZhou Inc. has announced the re-election and appointment of directors and supervisors for the third session of its Board and Supervisory Committee. The current executive directors are Lim Hou-Sen, Liqiao Ma, and Meirong Liu. The non-executive directors include Ao Zhang and Wei Wang, while the independent non-executive directors are Ting Yuk Anthony Wu, Chi Wai Suen, and John Junhua Gu.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief on May 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL5L052x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","02500","BK1100"],"gpt_icon":0},{"id":"2539226475","title":"Zylox-Tonbridge Medical Technology Co. Ltd. Convened Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539226475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539226475?lang=en_us&edition=fundamental","pubTime":"2025-05-30 18:46","pubTimestamp":1748602017,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge Medical Technology Co., Ltd. held its 2024 Annual General Meeting on May 30, 2025. All proposals presented at the meeting were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief on May 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL3Ct7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1583","BK1574","BK1100","02190"],"gpt_icon":0},{"id":"2539226990","title":"Zylox-Tonbridge Medical Technology Co. Ltd. Announces Final Dividend of RMB 0.1 Per Share for Year Ended 31 December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2539226990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539226990?lang=en_us&edition=fundamental","pubTime":"2025-05-30 18:45","pubTimestamp":1748601905,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge Medical Technology Co., Ltd. has announced a final dividend of RMB 0.1 per share for the financial year ending 31 December 2024. The dividend will be paid in Hong Kong dollars at a rate of HKD 0.1089909 per share, following an updated exchange rate. Shareholders' approval for this dividend was obtained on 30 May 2025, with the payment date set for 27 June 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief on May 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL3jQvgc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1100","BK1583","BK1574","02190"],"gpt_icon":0},{"id":"2539247240","title":"Hansoh Pharmaceutical - Third Biologics License Application of Xinyue (Inebilizumab Injection) Was Accepted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2539247240","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539247240?lang=en_us&edition=fundamental","pubTime":"2025-05-30 17:45","pubTimestamp":1748598300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S203N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1589","BK1191","03692"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":99,"code":"91000000","status":"200"}]}}